Shots:
- The US FDA has granted BDD to Airiver Pulmonary Drug Coated Balloon (DCB) to treat central airway stenosis
- Additionally, the first patient has been enrolled & treated in a trial evaluating the Airiver DCB vs SoC bare balloon dilation in ~200 pts with central airway stenosis; positive results could support a future FDA regulatory submission
- Airiver DCB combines balloon dilation to reopen the airway with localized paclitaxel delivery via a proprietary coating designed to prolong symptom relief & reduce stenosis, while minimizing drug exposure to surrounding healthy tissue
Ref: PRnewswire | Image: Airiver Medical | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
